DeepMed Research

Akeso

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: $5B

Website

Clinical Trials

Study of AK119 in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: AK119

First Posted Date: 2021-12-30

Last Posted Date: 2024-04-25

Lead Sponsor: Akeso

Target Recruit Count: 16

Registration Number: NCT05173792

Locations: 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, China
🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Biological: AK120
Biological: Placebo

First Posted Date: 2021-12-13

Last Posted Date: 2022-10-12

Lead Sponsor: Akeso

Target Recruit Count: 1

Registration Number: NCT05155020

Locations: 🇨🇳
Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, China
🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Beijing Jingmei General Hospital, Beijing, Beijing, China

and more 16 locations

A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: AK109+AK104

First Posted Date: 2021-12-02

Last Posted Date: 2025-03-12

Lead Sponsor: Akeso

Target Recruit Count: 198

Registration Number: NCT05142423

Locations: 🇨🇳
First affliated hospital of Zhejiang University, Hangzhou, Zhejiang, China

A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

Phase 3

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: AK101
Drug: Placebo

First Posted Date: 2021-11-15

Last Posted Date: 2023-03-02

Lead Sponsor: Akeso

Target Recruit Count: 452

Registration Number: NCT05120297

Locations: 🇨🇳
AkesoBio Investigative Site 1028, Hefei, Anhui, China
🇨🇳
AkesoBio Investigative Site 1013, Wuhu, Anhui, China
🇨🇳
AkesoBio Investigative Site 1027, Beijing, Beijing, China

and more 49 locations

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Phase 1

Completed

Conditions: SCLC, Extensive Stage

Interventions: Drug: AK112
Drug: Etoposide
Drug: Carboplatin

First Posted Date: 2021-11-10

Last Posted Date: 2024-05-31

Lead Sponsor: Akeso

Target Recruit Count: 35

Registration Number: NCT05116007

Locations: 🇨🇳
Shun Lu, Shanghai, Shanghai, China

A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Biological: AK111/Placebo

First Posted Date: 2021-10-27

Last Posted Date: 2025-02-28

Lead Sponsor: Akeso

Target Recruit Count: 251

Registration Number: NCT05096364

Locations: 🇨🇳
AkesoBio Investigative Site 1012, Chengde, Hebei, China
🇨🇳
AkesoBio Investigative Site 1008, Changsha, Hunan, China
🇨🇳
AkesoBio Investigative Site 1007, Guangzhou, Guangdong, China

and more 10 locations

A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Phase 3

Active, not recruiting

Conditions: Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma

Interventions: Drug: Placebo
Drug: AK104

First Posted Date: 2021-08-17

Last Posted Date: 2025-03-07

Lead Sponsor: Akeso

Target Recruit Count: 610

Registration Number: NCT05008783

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳
The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou, Zhejiang, China
🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China

and more 4 locations

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

Phase 1

Terminated

Conditions: Recurrent Ovarian Carcinoma
Relapsed Ovarian Cancer
Ovarian Cancer
Ovarian Neoplasms

Interventions: Drug: AK112 low dose
Drug: AK112 medium dose
Drug: AK112 high dose

First Posted Date: 2021-08-11

Last Posted Date: 2024-01-05

Lead Sponsor: Akeso

Target Recruit Count: 8

Registration Number: NCT04999605

Locations: 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3

Active, not recruiting

Conditions: Cervical Cancer

Interventions: Biological: AK104
Drug: paclitaxel
Drug: cisplatin
Drug: carboplatin
Drug: bevacizumab
Drug: Placebo

First Posted Date: 2021-07-29

Last Posted Date: 2025-03-04

Lead Sponsor: Akeso

Target Recruit Count: 445

Registration Number: NCT04982237

Locations: 🇨🇳
The Second Affiliated Hospital,Anhui Medical University, Hefei, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳
Women's Hospital School Of Medicine Zhejiang University, Hangzhou, China

and more 2 locations

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Phase 1

Recruiting

Conditions: Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: AK109
Drug: paclitaxel
Biological: AK104

First Posted Date: 2021-07-29

Last Posted Date: 2024-06-28

Lead Sponsor: Akeso

Target Recruit Count: 138

Registration Number: NCT04982276

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy